Gross Margin: 66.88%
Is the gross margin high or low?
The gross margin of 66.88% is in line with its 5-year average of 66.81%, around the middle of its 5-year range (62.72%–69.51%).
As of Saturday, June 27, 2026. 2.03% above its 12-month average of 65.55%.
TECH Gross Margin
Reported quarterly gross margin; no daily interpolation.
TECH Average Gross Margin Chart
TECH Current vs Average Gross Margin Chart
TECH Gross Margin Metrics
GROSS MARGIN
66.88%
GROSS MARGIN AVG TTM
65.55%
GROSS MARGIN AVG 3Y
66.03%
GROSS MARGIN AVG 5Y
66.81%
GROSS MARGIN AVG 10Y
66.55%
GROSS MARGIN AVG 15Y
67.36%
GROSS MARGIN AVG 20Y
70.96%
CURRENT VS TTM AVG
+2.03%
CURRENT VS 3Y AVG
+1.29%
CURRENT VS 5Y AVG
+0.11%
CURRENT VS 10Y AVG
+0.51%
CURRENT VS 15Y AVG
-0.71%
CURRENT VS 20Y AVG
-5.74%
TECH Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 66.88% | 65.55% | 66.03% | 66.81% |
| Insulet Corp. (PODD)vs › | $10.96B | 71.01% | 70.71% | 67.87% | 67.39% |
| Baxter International Inc. (BAX)vs › | $11.38B | 30.11% | 33.76% | 35.72% | 36.84% |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | 8.47% | 10.31% | 11.40% | 11.87% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 17.13% | 18.71% | 19.98% | 20.79% |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.20B | 31.86% | 31.70% | 34.15% | 35.17% |
| Tempus AI, Inc. (TEM)vs › | $9.80B | 69.55% | 62.30% | 54.75% | 44.45% |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 29.69% | 29.43% | 29.32% | 29.12% |
| Revvity, Inc. (RVTY)vs › | $12.61B | 51.44% | 50.55% | 50.58% | 52.43% |
| Align Technology, Inc. (ALGN)vs › | $12.78B | 67.68% | 69.16% | 69.73% | 70.75% |
Gross Margin Analysis
Gross Margin
66.9%
(Revenue - COGS) / Revenue
Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gross Margin FAQ
- What is the gross margin for Bio-Techne Corporation (TECH)?
- The gross margin for TECH stock is 66.88%.
- Is Bio-Techne Corporation's gross margin high or low?
- The gross margin of 66.88% is in line with its 5-year average of 66.81%, around the middle of its 5-year range (62.72%–69.51%).
- What is the TTM average gross margin for Bio-Techne Corporation (TECH)?
- The TTM average gross margin for TECH stock is 65.55%.
- What is the 3Y average gross margin for Bio-Techne Corporation (TECH)?
- The 3Y average gross margin for TECH stock is 66.03%.
- What is the 5Y average gross margin for Bio-Techne Corporation (TECH)?
- The 5Y average gross margin for TECH stock is 66.81%.
- What is the 10Y average gross margin for Bio-Techne Corporation (TECH)?
- The 10Y average gross margin for TECH stock is 66.55%.
- What is the 15Y average gross margin for Bio-Techne Corporation (TECH)?
- The 15Y average gross margin for TECH stock is 67.36%.
- What is the 20Y average gross margin for Bio-Techne Corporation (TECH)?
- The 20Y average gross margin for TECH stock is 70.96%.
TECH Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 66.88% |
| 2025-12-31 | 64.65% |
| 2025-09-30 | 65.65% |
| 2025-06-30 | 62.72% |
| 2025-03-31 | 67.86% |
| 2024-12-31 | 65.27% |
| 2024-09-30 | 63.23% |
| 2024-06-30 | 66.43% |
| 2024-03-31 | 67.43% |
| 2023-12-31 | 64.78% |
| 2023-09-30 | 66.87% |
| 2023-06-30 | 67.93% |
| 2023-03-31 | 68.73% |
| 2022-12-31 | 67.52% |
| 2022-09-30 | 66.60% |
| 2022-06-30 | 69.51% |
| 2022-03-31 | 69.38% |
| 2021-12-31 | 68.22% |
| 2021-09-30 | 66.35% |
| 2021-06-30 | 67.92% |
| 2021-03-31 | 69.09% |
| 2020-12-31 | 67.29% |
| 2020-09-30 | 67.45% |
| 2020-06-30 | 64.44% |
| 2020-03-31 | 66.81% |
| 2019-12-31 | 65.65% |
| 2019-09-30 | 64.62% |
| 2019-06-30 | 66.92% |
| 2019-03-31 | 67.41% |
| 2018-12-31 | 64.76% |
| 2018-09-30 | 66.03% |
| 2018-06-30 | 67.78% |
| 2018-03-31 | 67.24% |
| 2017-12-31 | 66.06% |
| 2017-09-30 | 67.68% |
| 2017-06-30 | 65.38% |
| 2017-03-31 | 65.39% |
| 2016-12-31 | 64.55% |
| 2016-09-30 | 64.69% |
| 2016-06-30 | 66.56% |
| 2016-03-31 | 68.71% |
| 2015-12-31 | 67.48% |
| 2015-09-30 | 67.09% |
| 2015-06-30 | 67.22% |
| 2015-03-31 | 69.54% |
| 2014-12-31 | 67.66% |
| 2014-09-30 | 67.36% |
| 2014-06-30 | 68.73% |
| 2014-03-31 | 71.28% |
| 2013-12-31 | 69.74% |
| 2013-09-30 | 71.34% |
| 2013-06-30 | 74.38% |
| 2013-03-31 | 75.50% |
| 2012-12-31 | 73.60% |
| 2012-09-30 | 74.09% |
| 2012-06-30 | 74.81% |
| 2012-03-31 | 75.80% |
| 2011-12-31 | 73.89% |
| 2011-09-30 | 75.24% |
| 2011-06-30 | 76.00% |
| 2011-03-31 | 79.24% |
| 2010-12-31 | 77.52% |
| 2010-09-30 | 77.57% |
| 2010-06-30 | 79.26% |
| 2010-03-31 | 79.51% |
| 2009-12-31 | 79.66% |
| 2009-09-30 | 80.61% |
| 2009-06-30 | 77.41% |
| 2009-03-31 | 78.91% |
| 2008-12-31 | 78.30% |
| 2008-09-30 | 81.12% |
| 2008-06-30 | 79.51% |
| 2008-03-31 | 79.65% |
| 2007-12-31 | 79.48% |
| 2007-09-30 | 79.13% |
| 2007-06-30 | 78.27% |
| 2007-03-31 | 80.03% |
| 2006-12-31 | 79.60% |
| 2006-09-30 | 78.54% |
| 2006-06-30 | 77.29% |
| 2006-03-31 | 77.92% |
| 2005-12-31 | 77.73% |
| 2005-09-30 | 76.74% |
| 2005-06-30 | 79.29% |
| 2005-03-31 | 80.94% |
| 2004-12-31 | 78.84% |
| 2004-09-30 | 78.28% |
| 2004-06-30 | 79.19% |
| 2004-03-31 | 78.97% |
| 2003-12-31 | 77.94% |
| 2003-09-30 | 77.20% |
| 2003-06-30 | 75.70% |
| 2003-03-31 | 76.80% |
| 2002-12-31 | 74.86% |
| 2002-09-30 | 74.85% |
| 2002-06-30 | 76.04% |
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman